Neuronetics, Inc.

STIM

US64131A1051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 11:56:03 2026-01-21 am EST			5-day change	1st Jan Change
1.985 ^USD	+2.58%		+12.71%	+44.57%

Nov. 04	Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025
Nov. 04	Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

William Blair Upgrades Neuronetics to Outperform From Market Perform

Published on 05/14/2024 at 07:43 am EDT - Modified on 05/14/2024 at 07:55 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Neuronetics, Inc.

Nov. 04	Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025
Nov. 04	Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 04	Keith J. Sullivan Intends to Retire as Chief Executive Officer of Neuronetics, Inc. on June 30, 2026	CI
Nov. 04	Keith J. Sullivan Intents to Retire as President of Neuronetics, Inc. on June 30, 2026	CI
Nov. 04	Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter 2025	CI
Nov. 04	Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025	CI
Nov. 04	Neuronetics Q3 revenue misses estimates	RE
25-10-30	Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand Neurostar Access and Operational Excellence	CI
25-09-21	Neuronetics, Inc.(NasdaqGM:STIM) added to S&P Global BMI Index	CI
25-09-17	Neuronetics - New York Medicaid to cover TMS services for adults with MDD	RE
25-08-05	Neuronetics, Inc., Q2 2025 Earnings Call, Aug 05, 2025
25-08-05	Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-05	Healthcare firm Neuronetics Q2 revenue beats estimates	RE
25-08-05	Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year Ending December 31, 2025	CI
25-07-15	Neuronetics, Inc. Announces Chief Financial Officer Changes	CI
25-07-15	Neuronetics appoints new chief financial officer	RE
25-07-15	Neuronetics Appoints Steven Pfanstiel as CFO	MT
25-07-15	Neuronetics, Inc. Appoints Steven Pfanstiel as Executive Vice President, and Treasurer	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 3000 Growth Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 2000 Dynamic Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell Small Cap Comp Growth Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 3000E Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 3000 Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 2500 Growth Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell Small Cap Completeness Index	CI

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Employees

716

Sector

Advanced Medical Equipment & Technology

Calendar

Mar. 09 - Q4 2025 Earnings Release (Projected)

More about the company